Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
Study findings from Burnham Institute for Medical Research broaden understanding of cancer vaccines
April 14th, 2009
Scientists discuss in 'Salmonella typhimurium engineered to produce CCL21 inhibit tumor growth' new findings in cancer. "Intravenously-applied bacteria tend to accumulate in tumors and can sporadically lead to tumor regression. Systemic administration of attenuated Salmonella typhimurium is safe and has shown no significant adverse effects in humans," investigators in the United States report. "The purpose of this study was to test the hypothesis that engineering S. typhimurium to express a chemokine, CCL21, would increase anti-tumor activity. We engineered an attenuated strain of S. typhimurium to produce the chemokine CCL21. Attenuated S....
Source: Cancer Weekly (2009-04-14)
|
